Constellation Brands
STZ
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Precision Drilling
PDS
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
Biomea Fusion Stock Forum
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug
Game-Changing Diabetes Treatment Restores Insulin Production: Clinical Trial Reveals 53% Improvement
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Monday, 24th March at 8:30 am
• Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib
• Strong correlation betwee...
Key clinical trial results for icovamenib showed:
1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
1.0% HbA1c reduction in patients on GLP-1-based therapies
100% response ...
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Monday, 13th January at 9:00 am
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones
of the metabolic franchise
Biomea preparing icovamenib for late-stage clinical development
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company...
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...
No comment yet